Alan Bryce

Title: Alan Bryce: Innovator in Targeted Cancer Therapies

Introduction

Alan Bryce is a notable inventor based in Scottsdale, AZ (US). He has made significant contributions to the field of cancer research, particularly in developing targeted therapies. With a total of 2 patents, his work focuses on innovative methods for detecting and treating cancers associated with NRG1 fusion events.

Latest Patents

Bryce's latest patents revolve around targeted therapies for cancer. These patents provide compositions and methods for detecting cancers that contain an NRG1 fusion event. The therapeutic agents he has developed are specifically targeted to this fusion, offering new hope for patients. Exemplary compositions include agents that inhibit Epidermal Growth Factor Receptor and/or ERBB2, such as cetuximab, panitumumab, Sym004, MM-151, mAb 806, mAb 528, MEHD794A, gefitinib, erlotinib, lapatinib, afatinib, PD153035, AG1478, trastuzumab, and pertuzumab. In some embodiments, the therapeutic agent may be a combination of trastuzumab and pertuzumab.

Career Highlights

Throughout his career, Alan Bryce has worked with esteemed organizations such as the Translational Genomics Research Institute and the Mayo Foundation for Medical Education and Research. His experience in these institutions has allowed him to collaborate with leading experts in the field.

Collaborations

Some of his notable coworkers include John Carpten and David Craig. Their collective expertise has contributed to advancements in cancer research and treatment.

Conclusion

Alan Bryce's innovative work in targeted cancer therapies highlights his commitment to improving patient outcomes. His patents and collaborations reflect a dedication to advancing medical science and providing new treatment options for cancer patients.